Abbott Laboratories vs. Cue Biopharma, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABT | CUE | |
|---|---|---|
| Market Cap | $177.55 billion | $269.15 million |
| Revenue (TTM) | $46.59 billion | $37.65 million |
| Net Income (TTM) | $5.42 billion | $-164,108,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | CUE | |
|---|---|---|
| P/E Ratio | 33.33 | — |
| Price / Book | 3.43 | 116.51 |
| Price / Sales | 3.81 | 7.15 |
ABT leads on 2 of 2 valuation factors.
Profitability
| ABT | CUE | |
|---|---|---|
| Net Margin | 11.65% | -435.83% |
| Return on Equity | 10.48% | -7104.24% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | CUE | |
|---|---|---|
| Dividend Yield | 2.45% | — |
| Payout Ratio | 81.55 | — |
ABT and CUE split the dividend factors evenly.
Risk & Sentiment
| ABT | CUE | |
|---|---|---|
| Short Interest | 0.57% | 0.48% |
CUE leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, CUE overview, CUE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.